ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年05月14日 13時00分
Source:
Eisai
エーザイ、代表執行役の異動に関するお知らせ
東京, 2019年05月14日 - (JCN Newswire) - 当社は、2019年5月13日開催の取締役会において、以下のとおり、代表執行役を異動することについて決議しましたので、お知らせします。
1. 代表執行役の異動
(退任予定代表執行役)
林 秀樹(現 代表執行役日本事業担当兼CIO 日本事業担当(兼)hhcソリューション本部担当(兼)チーフインフォメーションオフィサー)
※林 秀樹は新任取締役候補者です。
2. 異動予定日
2019年6月20日
3. 新しい代表執行役体制
2019年6月20日以降の新しい代表執行役体制は以下の通りとなる予定です。
代表執行役CEO 内藤 晴夫(現 代表執行役CEO)
代表執行役COO 岡田 安史(現 代表執行役CTO兼業界担当兼中国事業担当)
※岡田 安史は、COOに就任する予定です。COOは、CEOを補佐し、社を代表して業界を担当することに加え、中国事業担当、データインテグリティ推進担当を担い、エーザイデマンドチェーンシステムズを管掌します。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201934.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
TANAKA to Showcase Advanced Semiconductor Materials in its Inaugural Participation at SEMICON India 2025
Aug 26, 2025 13:30 JST
Honda to Hold Official e-Motorsports Event, "Honda Racing eMS 2025"
Aug 26, 2025 13:17 JST
Mitsubishi Corporation Invests in Fullerton Health
Aug 26, 2025 12:54 JST
Queensland's First Nations businesses forge global trade links
Aug 26, 2025 10:00 JST
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 25, 2025 19:30 JST
Shibaura Institute of Technology, Waseda University and Fujitsu develop quantum computer-based robot posture optimization
Aug 25, 2025 18:22 JST
NEC technology predicts sudden traffic congestion in real time using optical fiber cables
Aug 25, 2025 17:30 JST
CITIC Resources Deepens Dual Driver Development Strategy of "Investment + Trading"
Aug 22, 2025 20:28 JST
CaoCao Inc. (2643.HK) Added to Hang Seng Composite Index, Set to Join Hong Kong Stock Connect on Sept 8
Aug 22, 2025 19:51 JST
China International Development Corporation acquires strategic 20% stake in NVT
Aug 22, 2025 09:22 JST
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Successfully Carries Out Space Protein Crystallization Experiments
Aug 22, 2025 03:00 JST
NEC digital technologies to empower small-scale producers in Africa in partnership with IFAD
Aug 21, 2025 20:32 JST
Sharp Corporation and Sharp Energy Solutions Corporation Sign Memorandum of Understanding with Mitsui O.S.K. Lines, and AAR Japan for Donation of Solar Modules to Kenya
Aug 21, 2025 20:15 JST
Aiming to Build Battery Ecosystem, Toyota and Mazda Start Tests of Energy Storage System Using Electrified Vehicle Batteries
Aug 21, 2025 19:50 JST
NEC signs Memorandum of Cooperation with the Senegalese government, CFPT-SJ, JICA, and four Japan-based companies for vocational training in Senegal
Aug 21, 2025 19:27 JST
Sharp Corporation and Sharp Energy Solutions Corporation Sign Memorandum of Understanding with Mitsui O.S.K. Lines, and IOM to Advance Cooperation through Renewable Energy
Aug 21, 2025 19:07 JST
Kingsoft Announces 2025 Interim and Second Quarter Results
Aug 21, 2025 12:16 JST
NEC develops robot control technology using AI to achieve safe, efficient autonomous movement even at sites with many obstacles
Aug 21, 2025 10:39 JST
Hengdeli Announces 2025 Interim Results
Aug 20, 2025 20:52 JST
Emperor W&J Announces 2025 Interim Results, Revenues from Hong Kong and Mainland China Increase by 9% Respectively
Aug 20, 2025 20:00 JST
More Latest Release >>
Related Release
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
8/25/2025 7:30:00 PM JST
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
8/18/2025 9:11:00 AM JST
Revenue of LEQEMBI(R) (Preliminary Basis)
7/31/2025 6:27:00 PM JST
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
7/31/2025 9:30:00 AM JST
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
7/31/2025 9:20:00 AM JST
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
7/31/2025 9:10:00 AM JST
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
7/29/2025 9:01:00 AM JST
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
7/25/2025 1:31:00 PM JST
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
7/23/2025 10:07:00 AM JST
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
7/22/2025 11:56:00 AM JST
More Press release >>